![Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial - The Lancet Oncology Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/49eb3bdf-e0df-4a9f-b5f2-51f115cb9c81/gr1.jpg)
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial - The Lancet Oncology
![Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer | British Journal of Cancer Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2013.151/MediaObjects/41416_2013_Article_BFbjc2013151_Fig1_HTML.jpg)
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer | British Journal of Cancer
![Additional 5 Years of Letrozole May Benefit Some Postmenopausal Women With Early-Stage Breast Cancer - The ASCO Post Additional 5 Years of Letrozole May Benefit Some Postmenopausal Women With Early-Stage Breast Cancer - The ASCO Post](https://ascopost.com/media/14001996/710-3_image.jpg)